» Articles » PMID: 7991730

Psychometric Properties of the Positive and Negative Syndrome Scale (PANSS) in Schizophrenia

Overview
Journal Psychiatry Res
Specialty Psychiatry
Date 1994 Jul 1
PMID 7991730
Citations 126
Authors
Affiliations
Soon will be listed here.
Abstract

We analyzed the psychometric properties of the Positive and Negative Syndrome Scale (PANSS) in a sample of 100 DSM-III-R schizophrenic patients. Our findings coincided with the results of Kay's group in the following points: (1) the PANSS scores were normally distributed; (2) the positive and negative scales showed good interrater reliability; (3) positive and negative syndromes are independent constructs; (4) the positive and negative scales held a high concurrent validity in relation to the Scale for the Assessment of Positive Symptoms and the Scale for the Assessment of Negative Symptoms; and (5) although positive and negative syndromes showed factorial validity, they were not sufficient to account for the whole of the schizophrenic symptoms. Unlike Kay's group, we found a modest internal consistency of the positive scale, indicating that it is composed of several independent components. The data suggest that the distinction between positive and negative symptoms is an oversimplification, and that schizophrenic symptoms can be better conceptualized as composed of, at least three dimensional syndromes: positive, disorganized, and negative.

Citing Articles

A generalisability theory approach to quantifying changes in psychopathology among ultra-high-risk individuals for psychosis.

Doborjeh Z, Medvedev O, Doborjeh M, Singh B, Sumich A, Budhraja S Schizophrenia (Heidelb). 2024; 10(1):87.

PMID: 39366985 PMC: 11452639. DOI: 10.1038/s41537-024-00503-y.


Unidentified genotype does not affect pharmacological treatment for patients with first episode psychosis.

De Brabander E, van Amelsvoort T, van Westrhenen R J Psychopharmacol. 2024; 38(12):1111-1121.

PMID: 39344086 PMC: 11528939. DOI: 10.1177/02698811241279022.


Clinical effects of CYP2D6 phenoconversion in patients with psychosis.

De Brabander E, Breddels E, van Amelsvoort T, van Westrhenen R J Psychopharmacol. 2024; 38(12):1095-1110.

PMID: 39310932 PMC: 11528948. DOI: 10.1177/02698811241278844.


The effects of ketogenic metabolic therapy on mental health and metabolic outcomes in schizophrenia and bipolar disorder: a randomized controlled clinical trial protocol.

Longhitano C, Finlay S, Peachey I, Swift J, Fayet-Moore F, Bartle T Front Nutr. 2024; 11:1444483.

PMID: 39234289 PMC: 11371693. DOI: 10.3389/fnut.2024.1444483.


Neuropsychological profiles in first-episodes psychosis and their relationship with clinical, metacognition and social cognition variables.

Espinosa V, Bagaeva A, Lopez-Carrilero R, Barajas A, Barrigon M, Birules I Eur Arch Psychiatry Clin Neurosci. 2024; .

PMID: 38806850 DOI: 10.1007/s00406-024-01813-z.